文献速递主动脉疾病

意大利国家注册研究关于Najuta开窗主动脉弓腔内移植物结局的初步结果

Preliminary results from an Italian National Registry on the outcomes of the Najuta fenestrated aortic arch endograft.
PubMed 文献 · J Vasc Surg · 2023-01-05

该前瞻性注册研究纳入2018至2022年意大利76例连续接受Najuta开窗腔内移植物的患者,回顾性分析围手术期数据。技术成功率为97.4%,30天临床成功率为94.7%,中位随访7个月无主动脉上血管闭塞或手术转换。作者认为在需要近端锚定区的主动脉弓病变患者中,该腔内方法安全有效,尤其适用于高手术风险者,需严格随访以确认初步发现。

要点

  • 技术成功率为97.4%(74/76),两例失败均与最终造影发现内漏相关。
  • 30天临床成功率为94.7%,30天内需2例早期再干预。
  • 中位随访7个月,无主动脉上血管闭塞,无患者需手术转换。

核心结论

  • 作者认为,在需要近端锚定区的选择性主动脉弓病变患者中,使用Najuta系统的腔内方法安全有效,尤其适用于高手术风险者;需严格随访以确认这些初步经验发现。

研究设计与样本

  • 前瞻性纳入意大利所有连续接受Najuta腔内移植物(Kawasumi Laboratories, Inc, Tokyo, Japan)治疗的患者,回顾性分析解剖特征和围手术期数据。
  • 2018年至2022年间,意大利76例患者接受Najuta腔内移植物并纳入研究;中位年龄72岁(四分位距69-76岁),80.3%为男性。

主要发现

  • 大多数患者因动脉粥样硬化性动脉瘤接受治疗(80.3%),其他为夹层后动脉瘤(7.9%)、穿透性主动脉溃疡(9.2%)或既往胸主动脉腔内修复术后I型内漏矫正(2.6%)。
  • 总体通过专用开窗保留161根主动脉上血管;技术成功率为97.4%(74/76),两例失败均与最终造影检测到内漏相关(一例I型、一例III型内漏);植入过程中发生两例远端迁移。
  • 30天临床成功率为94.7%;30天内有2例早期再干预:一例因远端再入口导致夹层后胸主动脉瘤增大而行主动脉假腔弹簧圈栓塞,另一例为股动脉假性动脉瘤修复。
  • 中位随访7个月(四分位距3-15个月);无主动脉上血管闭塞发生,无患者需要手术转换。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要严格随访并采用高质量计算机断层扫描血管造影图像以及时评估长期并发症,以确认这些初步经验发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arch pathology represents one of the last frontiers in aortic aneurysm endovascular management. Several companies recently developed dedicated branched and fenestrated endografts specifically designed for the aortic arch, aiming to overcome some of the issues associated with standard thoracic endograft and supra-aortic vessels extra-anatomic debranching. This study aimed to evaluate early outcomes obtained with a custom-made fenestrated endograft approved for thoracic aortic aneurysms exclusion. METHODS: All consecutive patients treated with the Najuta endograft (Kawasumi Laboratories, Inc, Tokyo, Japan) in Italy were enrolled prospectively and included in the study population. Anatomic characteristics and perioperative data were analyzed retrospectively. Study end points were technical success, 30-day clinical success, overall survival, supra-aortic vessel patency, endoleak, and need for reintervention or surgical conversion. RESULTS: Between 2018 and 2022, 76 patients received a Najuta endograft in Italy and were enrolled in the study. The median patient age was 72 years (interquartile range, 69-76 years) and 80.3% were male. Most of the patients received treatment for atherosclerotic aneurysms (80.3%); others were treated for postdissection aneurysms (7.9%), penetrating aortic ulcer (9.2%), or type I endoleak correction after previous thoracic endovascular repair (2.6%). Overall, 161 supra-aortic vessels were preserved through a dedicated fenestration. Technical success was achieved in 74 of 76 procedure (97.4%); both failures were associated with endoleak detection at final angiography (one type I and one type III endoleak). Two distal migrations occurred during the implanting procedure. Clinical success at 30 days was 94.7%. Two early reinterventions were needed within 30 days after index procedure: in one case, an aortic false lumen coils embolization was performed, because distal re-entry caused enlargement of the postdissection thoracic aneurysm. The other procedure consisted of a femoral pseudoaneurysm repair. The median follow-up was 7 months (interquartile range, 3-15 months); no supra-aortic vessel occlusions occurred and no patients needed surgical conversion. CONCLUSIONS: Early results suggest that, in selected patients with aortic arch pathology needing a proximal landing, an endovascular approach with the Najuta system is safe and effective, especially for those at high surgical risk. A strict follow-up with high-quality computed tomography angiography images and eventual evaluation for long-term complications is needed to confirm these initial experience findings.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Isernia G, Simonte G, Orrico M, et al. Preliminary results from an Italian National Registry on the outcomes of the Najuta fenestrated aortic arch endograft. J Vasc Surg. 2023. PMID: 36621617. doi:10.1016/j.jvs.2022.12.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。